The present and prospective situation of infliximab in treatment of Crohn's disease
HAN Ying
LI Shi-rong
Abstract：Infliximab,an anti-TNF-α chimeric monoclonal anti body product,was approved by US FDA in 1998 for use in treatment of resistant Cr ohn's disease.The present and prospective situations of infliximab are reviewed by the authors
Machine-generated Keywords：
Publication Date：2001-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 164-167 )